参考文献/References:
[1] Bommer C,Sagalova V,Heesemann E,et al.Global economic burden of diabetes in adults:projections from 2015 to 2030[J].Diabetes Care,2018,41(5):963-970.DOI:10.2337/dc17-1962.
[2] Cefalu WT,Richards RJ,Melendez-Ramirez LY.Redefining treatment success in type 2 diabetes mellitus:comprehensive targeting of core defects[J].Cleve Clin J Med,2009,76 Suppl 5:S39-S47.DOI:10.3949/ccjm.76.s5.06.
[3] Pinti MV,Fink GK,Hathaway QA,et al.Mitochondrial dysfunction in type 2 diabetes mellitus:an organ-based analysis[J].Am J Physiol Endocrinol Metab,2019,316(2):E268-E285.DOI:10.1152/ajpendo.00314.2018.
[4] Yendapally R,Sikazwe D,Kim SS,et al.A review of phenformin,metformin,and imeglimin[J].Drug Dev Res,2020,81(4):390-401.DOI:10.1002/ddr.21636.
[5] Pirags V,Lebovitz H,Fouqueray P.Imeglimin,a novel glimin oral antidiabetic,exhibits a good efficacy and safety profile in type 2 diabetic patients[J].Diabetes Obes Metab,2012,14(9):852-858.DOI:10.1111/j.1463-1326.2012.01611.x.
[6] Fouqueray P,Perrimond-Dauchy S,Bolze S.Imeglimin does not induce clinically relevant pharmacokinetic interactions when combined with either metformin or sitagliptin in healthy subjects[J].Clin Pharmacokinet,2020,59(10):1261-1271.DIO:10.1007/s40262-020-00886-y.
[7] Clémence C,Fouqueray P,Sébastien B.In vitro investigation,pharmacokinetics,and disposition of imeglimin,a novel oral antidiabetic drug,in preclinical species and humans[J].Drug Metab Dispos,2020,48(12):1330-1346.DOI:10.1124/dmd.120.000154.
[8] Chevalier C,Dubourg J,Bolze S,et al.Pharmacokinetics of imeglimin in subjects with moderate hepatic impairment[J].Clin Pharmacokinet,2021,60(4):485-490.DOI:10.1007/s40262-020-00948-1.
[9] Vial G,Chauvin MA,Bendridi N,et al.Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat,high-sucrose diet mice model[J].Diabetes,2015,64(6):2254-2264.DOI:10.2337/db14-1220.
[10] Prasad RB,Groop L.Precision medicine in type 2 diabetes[J].J Intern Med,2019,285(1):40-48.DOI:10.1111/joim.12859.
[11] Fouqueray P,Leverve X,Fontaine E,et al.Imeglimin-a new oral anti-diabetic that targets the three key defects of type 2 diabetes[J].J Diabetes Metab,2011,2(4):4-12.DOI:10.4172/2155-6156.1000126.
[12] Perry RJ,Cardone RL,Petersen MC,et al.Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents[J].Am J Physiol Endocrinol Metab,2016,311(2):E461-E470.DOI:10.1152/ajpendo.00009.2016.
[13] Wagner F,Vogt J,Wachter U,et al.Effects of the antidiabetic imeglimin in hyperglycemic mice with septic shock[J].Critical Care,2012,16(1 Suppl 1).DOI:10.1186/cc10628.
[14] Yaribeygi H,Maleki A,Sathyapalan T,et al.Molecular mechanisms by which imeglimin improves glucose homeostasis[J].J Diabetes Res,2020,2020:8768954.DOI:10.1155/2020/8768954.
[15] Pacini G,Mari A,Fouqueray P,et al.Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes[J].Diabetes Obes Metab,2015,17(6):541-545.DOI:10.1111/dom.12452.
[16] Hallakou-Bozec S,Kergoat M,Fouqueray P,et al.Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action[J].PLoS one,2021,16(2):e0241651.DOI:10.1371/journal.pone.0241651.
[17] Lablanche S,Tubbs E,Cottet-Rousselle C,et al.Imeglimin protects INS-1 cells and human islets against high glucose-and high fructose-induced cell death by inhibiting the mitochondrial PTP opening[J].Diabetes,2018,67(Suppl 1):81-OR.DOI:10.2337/db18-81-OR.
[18] Hallakou-Bozec S,Kergoat M,Moller DE,et al.Imeglimin preserves islet β-cell mass in type 2 diabetic ZDF rats[J].Endocrinol Diabetes Metab,2020,4(2):e00193.DOI:10.1002/edm2.193.
[19] Detaille D,Via G,Borel AL,et al.Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration[J].Cell Death Discov,2016,2(1):15072.DOI:10.1038/cddiscovery.2015.72.
[20] Li J,Shirakawa J,Togashi Y,et al.Imeglimin modulated ER stress to prevent ß-cell apoptosis induced by high glucose or thapsigargin[J].Diabetes,2019,68(P2013).DOI:10.2337/db19-2130-p.
[21] Lachaux M,Soulié M,Hamzaoui M,et al.Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome[J].Endocrinol Diabetes Metab,2020,3(3):e00128.DOI:10.1002/edm2.128.
[22] Johansson KS,Brønden A,Knop FK,et al.Clinical pharmacology of imeglimin for the treatment of type 2 diabetes[J].Expert Opin Pharmacother,2020,21(8):871-882.DIO:10.1080/14656566.2020.1729123.
[23] Pirags V,Lebovitz H,Fouqueray P.Imeglimin,a novel glimin oral antidiabetic,exhibits a good efficacy and safety profile in type 2 diabetic patients[J].Diabetes Obes Metab,2012,14(9):852-858.DIO:10.1111/j.1463-1326.
[24] Dubourg J,Ueki K,Grouin JM,et al.Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes:a 24-week,randomized,double-blind,placebo-controlled,dose-ranging phase 2b trial[J].Diabetes Obes Metab,2021,23(3):800-810.DIO:10.1111/dom.14285.
[25] Fouqueray P,Pirags V,Inzucchi SE,et al.The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy[J].Diabetes Care,2013,36:565-568.DIO:10.2337/dc12-0453.
[26] Fouqueray P,Pirags V,Diamant M,et al.The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy[J].Diabetes Care,2014,37(7):1924-1930.DIO:10.2337/dc13-2349.
[27] Dubourg J,Fouqueray P,Thang C.Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes(TIMES 1):a double-blind,randomized,placebo-controlled,parallel-group,multicenter phase 3 trial[J].Diabetes Care,2021,44(4):952-959.DIO:10.2337/dc20-0763.
[1] Bommer C,Sagalova V,Heesemann E,et al.Global economic burden of diabetes in adults:projections from 2015 to 2030[J].Diabetes Care,2018,41(5):963-970.DOI:10.2337/dc17-1962.
[2] Cefalu WT,Richards RJ,Melendez-Ramirez LY.Redefining treatment success in type 2 diabetes mellitus:comprehensive targeting of core defects[J].Cleve Clin J Med,2009,76 Suppl 5:S39-S47.DOI:10.3949/ccjm.76.s5.06.
[3] Pinti MV,Fink GK,Hathaway QA,et al.Mitochondrial dysfunction in type 2 diabetes mellitus:an organ-based analysis[J].Am J Physiol Endocrinol Metab,2019,316(2):E268-E285.DOI:10.1152/ajpendo.00314.2018.
[4] Yendapally R,Sikazwe D,Kim SS,et al.A review of phenformin,metformin,and imeglimin[J].Drug Dev Res,2020,81(4):390-401.DOI:10.1002/ddr.21636.
[5] Pirags V,Lebovitz H,Fouqueray P.Imeglimin,a novel glimin oral antidiabetic,exhibits a good efficacy and safety profile in type 2 diabetic patients[J].Diabetes Obes Metab,2012,14(9):852-858.DOI:10.1111/j.1463-1326.2012.01611.x.
[6] Fouqueray P,Perrimond-Dauchy S,Bolze S.Imeglimin does not induce clinically relevant pharmacokinetic interactions when combined with either metformin or sitagliptin in healthy subjects[J].Clin Pharmacokinet,2020,59(10):1261-1271.DIO:10.1007/s40262-020-00886-y.
[7] Clémence C,Fouqueray P,Sébastien B.In vitro investigation,pharmacokinetics,and disposition of imeglimin,a novel oral antidiabetic drug,in preclinical species and humans[J].Drug Metab Dispos,2020,48(12):1330-1346.DOI:10.1124/dmd.120.000154.
[8] Chevalier C,Dubourg J,Bolze S,et al.Pharmacokinetics of imeglimin in subjects with moderate hepatic impairment[J].Clin Pharmacokinet,2021,60(4):485-490.DOI:10.1007/s40262-020-00948-1.
[9] Vial G,Chauvin MA,Bendridi N,et al.Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat,high-sucrose diet mice model[J].Diabetes,2015,64(6):2254-2264.DOI:10.2337/db14-1220.
[10] Prasad RB,Groop L.Precision medicine in type 2 diabetes[J].J Intern Med,2019,285(1):40-48.DOI:10.1111/joim.12859.
[11] Fouqueray P,Leverve X,Fontaine E,et al.Imeglimin-a new oral anti-diabetic that targets the three key defects of type 2 diabetes[J].J Diabetes Metab,2011,2(4):4-12.DOI:10.4172/2155-6156.1000126.
[12] Perry RJ,Cardone RL,Petersen MC,et al.Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents[J].Am J Physiol Endocrinol Metab,2016,311(2):E461-E470.DOI:10.1152/ajpendo.00009.2016.
[13] Wagner F,Vogt J,Wachter U,et al.Effects of the antidiabetic imeglimin in hyperglycemic mice with septic shock[J].Critical Care,2012,16(1 Suppl 1).DOI:10.1186/cc10628.
[14] Yaribeygi H,Maleki A,Sathyapalan T,et al.Molecular mechanisms by which imeglimin improves glucose homeostasis[J].J Diabetes Res,2020,2020:8768954.DOI:10.1155/2020/8768954.
[15] Pacini G,Mari A,Fouqueray P,et al.Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes[J].Diabetes Obes Metab,2015,17(6):541-545.DOI:10.1111/dom.12452.
[16] Hallakou-Bozec S,Kergoat M,Fouqueray P,et al.Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action[J].PLoS one,2021,16(2):e0241651.DOI:10.1371/journal.pone.0241651.
[17] Lablanche S,Tubbs E,Cottet-Rousselle C,et al.Imeglimin protects INS-1 cells and human islets against high glucose-and high fructose-induced cell death by inhibiting the mitochondrial PTP opening[J].Diabetes,2018,67(Suppl 1):81-OR.DOI:10.2337/db18-81-OR.
[18] Hallakou-Bozec S,Kergoat M,Moller DE,et al.Imeglimin preserves islet β-cell mass in type 2 diabetic ZDF rats[J].Endocrinol Diabetes Metab,2020,4(2):e00193.DOI:10.1002/edm2.193.
[19] Detaille D,Via G,Borel AL,et al.Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration[J].Cell Death Discov,2016,2(1):15072.DOI:10.1038/cddiscovery.2015.72.
[20] Li J,Shirakawa J,Togashi Y,et al.Imeglimin modulated ER stress to prevent ß-cell apoptosis induced by high glucose or thapsigargin[J].Diabetes,2019,68(P2013).DOI:10.2337/db19-2130-p.
[21] Lachaux M,Soulié M,Hamzaoui M,et al.Short-and long-term administration of imeglimin counters cardiorenal dysfunction in a rat model of metabolic syndrome[J].Endocrinol Diabetes Metab,2020,3(3):e00128.DOI:10.1002/edm2.128.
[22] Johansson KS,Brønden A,Knop FK,et al.Clinical pharmacology of imeglimin for the treatment of type 2 diabetes[J].Expert Opin Pharmacother,2020,21(8):871-882.DIO:10.1080/14656566.2020.1729123.
[23] Pirags V,Lebovitz H,Fouqueray P.Imeglimin,a novel glimin oral antidiabetic,exhibits a good efficacy and safety profile in type 2 diabetic patients[J].Diabetes Obes Metab,2012,14(9):852-858.DIO:10.1111/j.1463-1326.
[24] Dubourg J,Ueki K,Grouin JM,et al.Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes:a 24-week,randomized,double-blind,placebo-controlled,dose-ranging phase 2b trial[J].Diabetes Obes Metab,2021,23(3):800-810.DIO:10.1111/dom.14285.
[25] Fouqueray P,Pirags V,Inzucchi SE,et al.The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy[J].Diabetes Care,2013,36:565-568.DIO:10.2337/dc12-0453.
[26] Fouqueray P,Pirags V,Diamant M,et al.The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy[J].Diabetes Care,2014,37(7):1924-1930.DIO:10.2337/dc13-2349.
[27] Dubourg J,Fouqueray P,Thang C.Efficacy and safety of imeglimin monotherapy versus placebo in Japanese patients with type 2 diabetes(TIMES 1):a double-blind,randomized,placebo-controlled,parallel-group,multicenter phase 3 trial[J].Diabetes Care,2021,44(4):952-959.DIO:10.2337/dc20-0763.
相似文献/References:
[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(04):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(04):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(04):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(04):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(04):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[6]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性
血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(04):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[7]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白
与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(04):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[8]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平
及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[9]陈双双,王楚媛,孔令芳.铬与2型糖尿病[J].国际内分泌代谢杂志,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
Chen Shuangshuang,Wang Chuyuan,Kong Lingfang.Chromium and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
[10]涂萍,许婷,段鹏,等.25-羟维生素D3补充对绝经后2型糖尿病
患者胰岛素敏感性及血糖控制的影响[J].国际内分泌代谢杂志,2016,36(05):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
Tu Ping,Xu Ting,Duan Peng,et al.Influence of 25-hydroxyvitamin D3 supplement on insulin sensitivity and glucose control in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(04):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]